glp 1 and glaucoma GLP-1s were huge in 2025, so this felt worth resurfacing as we kick off the year. 👁️ This review looks at GLP-1 receptor agonists ocular disease: possible protective signals in POAG GLP-1 Receptor Agonists Could Reduce

How one person metabolizes a medication and experiences side effects can be dramatically different from another

Importantly, the review also notes that individual responses to incretin-based therapies can vary substantially, and weight regain commonly occurs if treatment is discontinued, highlighting the chronic nature of obesity management

This is a blossoming market, Barrett said

At Smiley Aesthetics, we see you: your hard work, your wins, your moments of doubt

Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, Di Salvo J, Epifani R, Piacevole A, Tagliaferri G, Rocco M, Iadicicco I, Docimo G, Rinaldi L, Sardu C, Salvatore T, Marfella R, Sasso FC (2023) Peripheral neuropathy in diabetes Mellitus: pathogenetic mechanisms and diagnostic options

Abstract Atherosclerosis is a chronic metabolic disorder driven by endothelial dysfunction, inflammation, oxidative stress, and progressive plaque remodeling